Results from a new clinical trial show that the drug sodium thiosulfate can protect the hearing of children with cancer undergoing treatment with the chemotherapy drug cisplatin.
The NCI Experimental Therapeutics (NExT) program works with researchers and top scientific experts to advance promising or novel cancer therapies from the earliest stages of research to human clinical trials.
Results from two clinical trials are expected to improve the outlook for people diagnosed with early-stage pancreatic cancer that can be treated with surgery
Several types of clinical trials are used in cancer research, including treatment trials, prevention trials, screening trials, and supportive and palliative care trials. This page discusses the different types of trials and the role each plays in cancer research.
Clinical trials to test new cancer treatments involve a series of steps, called phases. If a new treatment is successful in one phase, it will proceed to further testing in the next phase. This page explains the different phases of cancer clinical trials.
NCI-Supported Clinical Trials That Are Recruiting Patients
This phase 2 trial is testing the drug olaparib in patients with malignant mesothelioma that has progressed despite treatment with chemotherapy. Olaparib interferes with the ability of cancer cells to repair their damaged DNA, causing them to die. Doctors hope that treatment with olaparib will shrink the tumors of people with malignant mesothelioma.
This phase 3 trial is testing the drug cabozantinib in patients with advanced, metastatic, or unresectable neuroendocrine tumors that have progressed after treatment with everolimus, an immunomodulatory drug. Doctors want to see if cabozantinib can improve progression-free and overall survival over a placebo in patients with pancreatic neuroendocrine tumors or advanced carcinoid tumors.
This phase 2 trial is testing bicalutamide, a hormone-targeted therapy, in combination with metformin, a commonly used diabetes drug. Doctor will determine if the combination therapy works better than bicalutamide alone to reverse rising PSA levels in overweight or obese men experiencing biochemical recurrence of prostate cancer after primary treatment.
